{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:48:25Z","timestamp":1782866905595,"version":"3.54.5"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["F31DK103520"],"award-info":[{"award-number":["F31DK103520"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.01572","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T09:02:16Z","timestamp":1595581336000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Targeting the Protective Arm of the Renin-Angiotensin System to Reduce Systemic Lupus Erythematosus Related Pathologies in MRL-lpr Mice"],"prefix":"10.3389","volume":"11","author":[{"given":"Maira","family":"Soto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Delatorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsie","family":"Hurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen E.","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/1529-0131(199901)42:1<46::AID-ANR6>3.0.CO;2-2","article-title":"Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992","volume":"42","author":"Uramoto","year":"1999","journal-title":"Arthritis Rheum."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00296-018-4091-4","article-title":"Real-world incidence and prevalence of systemic lupus erythematosus in Alberta, Canada","volume":"38","author":"Fatoye","year":"2018","journal-title":"Rheumatol Int."},{"key":"B3","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/rheumatology\/kev346","article-title":"Use of biologics in SLE: a review of the evidence from a clinical perspective","volume":"55","author":"Aytan","year":"2016","journal-title":"Rheumatology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e000380","DOI":"10.1136\/lupus-2019-000380","article-title":"String of successful trials in SLE: have we cracked the code?","volume":"7","author":"van Vollenhoven","year":"2020","journal-title":"Lupus Sci Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"i64","DOI":"10.1136\/ard.2010.142208","article-title":"Targeted therapies in systemic lupus erythematosus: successes, failures and future","volume":"70","author":"Hahn","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41584-019-0235-5","article-title":"New therapies for systemic lupus erythematosus \u2014 past imperfect, future tense","volume":"15","author":"Murphy","year":"2019","journal-title":"Nat Rev Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.3389\/fimmu.2018.02658","article-title":"Novel treatments in lupus","volume":"9","author":"Vukelic","year":"2018","journal-title":"Front Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e000239","DOI":"10.1136\/lupus-2017-000239","article-title":"Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments","volume":"4","author":"Touma","year":"2017","journal-title":"Lupus Sci Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1191\/0961203303lu391oa","article-title":"Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report","volume":"12","author":"Lockshin","year":"2003","journal-title":"Lupus."},{"key":"B10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1191\/0961203305lu2200oa","article-title":"Cardiac involvement in systemic lupus erythematosus","volume":"14","author":"Doria","year":"2005","journal-title":"Lupus."},{"key":"B11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejim.2020.01.013","article-title":"Cardiac and vascular damage in systemic erythematosus lupus. is disease activity the mediator?","volume":"73","author":"Pucci","year":"2020","journal-title":"Eur J Intern Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.10.017","article-title":"Update on lupus nephritis: core curriculum 2020","author":"Parikh","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"E345","DOI":"10.1152\/ajpendo.00456.2007","article-title":"Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-\u03baB activation via NADPH oxidase","volume":"294","author":"Wei","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11906-006-0050-7","article-title":"Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress","volume":"8","author":"Ferder","year":"2006","journal-title":"Curr Hypertension Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"E132","DOI":"10.1152\/ajpendo.00629.2010","article-title":"Angiotensin II plays a critical role in diabetic pulmonary fibrosis most likely via activation of NADPH oxidase-mediated nitrosative damage","volume":"301","author":"Yang","year":"2011","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"B17","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1161\/01.HYP.0000040262.48405.A8","article-title":"Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling","volume":"40","author":"Ogihara","year":"2002","journal-title":"Hypertension."},{"key":"B18","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/1440-1681.12168","article-title":"Protective arms of the renin\u2013angiotensin-system in neurological disease","volume":"40","author":"Sumners","year":"2013","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s11906-014-0440-1","article-title":"The protective arms of the renin-angiontensin system in stroke","volume":"16","author":"McCarthy","year":"2014","journal-title":"Curr Hypertens Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/bph.12159","article-title":"ACE2, angiotensin-(1-7) and mas receptor axis in inflammation and fibrosis","volume":"169","author":"Silva","year":"2013","journal-title":"Br J Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.jss.2013.06.052","article-title":"Angiotensin-(1-7) attenuates lung fibrosis by way of mas receptor in acute lung injury","volume":"185","author":"Chen","year":"2013","journal-title":"J Surg Res."},{"key":"B22","first-page":"761","article-title":"Association of angiotensin-converting enzyme gene dimorphisms with severity of lupus disease","volume":"19","author":"Rabbani","year":"2008","journal-title":"Saudi J Kidney Dis Transpl."},{"key":"B23","first-page":"141","article-title":"Association of an insertion polymorphism of angiotensin-converting enzyme gene with the activity of lupus nephritis","volume":"51","author":"Akai","year":"1999","journal-title":"Clin Nephrol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1038\/sj.gene.6363907","article-title":"Association of angiotensin-converting enzyme polymorphisms with systemic lupus erythematosus and nephritis: analysis of 644 SLE families","volume":"3","author":"Parsa","year":"2002","journal-title":"Genes Immun."},{"key":"B25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/0961203311418268","article-title":"Angiotensin-converting enzyme (ACE) serum levels and gene polymorphism in egyptian patients with systemic lupus erythematosus","volume":"21","author":"Abbas","year":"2012","journal-title":"Lupus."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1093\/rheumatology\/ken208","article-title":"Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus\u2013results from LUMINA (LIX): a multiethnic US cohort","volume":"47","author":"Dur\u00e1n-Barrag\u00e1n","year":"2008","journal-title":"Rheumatology."},{"key":"B27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1124\/jpet.103.053678","article-title":"Angiotensin inhibition reduces glomerular damage and renal chemokine expression in MRL\/lpr mice","volume":"307","author":"Lema","year":"2003","journal-title":"J Pharmacol Exp Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/BF02003227","article-title":"Differential effects of captopril and enalapril, two angiotensin converting enzyme inhibitors, on immune reactivity in experimental lupus disease","volume":"31","author":"Tarkowski","year":"1990","journal-title":"Agents Act."},{"key":"B29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.clim.2010.03.008","article-title":"Effect of combining ACE inhibitor and statin in lupus-prone mice","volume":"136","author":"Shimazu","year":"2010","journal-title":"Clin Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1084\/jem.20180776","article-title":"Lupus antibodies induce behavioral changes mediated by microglia and blocked by ACE inhibitors","volume":"215","author":"Nestor","year":"2018","journal-title":"J Exp Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1210\/en.2011-2031","article-title":"Angiotensin-(1-7) administration reduces oxidative stress in diabetic bone marrow","volume":"153","author":"Mordwinkin","year":"2012","journal-title":"Endocrinology."},{"key":"B32","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.1111\/bph.13225","article-title":"Angiotensin-(1-7) administration benefits cardiac, renal and progenitor cell function in db\/dbmice","volume":"172","author":"Papinska","year":"2015","journal-title":"Br J Pharmacol."},{"key":"B33","first-page":"149","article-title":"Detection of circulating immune complexes in MRL mice with different forms of glomerulonephritis","volume":"33","author":"Hewicker","year":"1990","journal-title":"Z Versuchstierkd."},{"key":"B34","first-page":"2567","article-title":"Cytokines in autoimmune lacrimal gland disease in MRL\/MpJ mice","volume":"42","author":"Jabs","year":"2001","journal-title":"Invest Ophth Vis Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s12016-017-8640-5","article-title":"Unmet needs in the pathogenesis and treatment of systemic lupus erythematosus","volume":"55","author":"Bakshi","year":"2017","journal-title":"Clin Rev Allerg Immu."},{"key":"B36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.clim.2016.08.015","article-title":"A systems approach to renal inflammation in SLE","volume":"185","author":"Berthier","year":"2017","journal-title":"Clin Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40256-015-0141-4","article-title":"Management of cardiovascular risk in patients with chronic inflammatory diseases: current evidence and future perspectives","volume":"16","author":"Lindhardsen","year":"2016","journal-title":"Am J Cardiovasc Drugs."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1002\/jcp.22940","article-title":"Angiotensin-(1-7) decreases LPS-induced inflammatory response in macrophages","volume":"227","author":"Souza","year":"2012","journal-title":"J Cell Physiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1038\/s41598-020-61250-5","article-title":"Angiotensin-[1-7] attenuates kidney injury in experimental alport syndrome","volume":"10","author":"Choi","year":"2020","journal-title":"Sci Rep."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1161\/HYPERTENSIONAHA.113.01764","article-title":"Angiotensin-(1\u20137) and kidney disease: friend or foe","volume":"62","author":"Velkoska","year":"2013","journal-title":"Hypertension."},{"key":"B41","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1113\/expphysiol.2013.075242","article-title":"Centrally administered angiotensin-(1-7) increases the survival of stroke-prone spontaneously hypertensive rats","volume":"99","author":"Regenhardt","year":"2014","journal-title":"Exp Physiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1042\/CS20120111","article-title":"Angiotensin-(1-7) in kidney disease: a review of the controversies","volume":"123","author":"Zimmerman","year":"2012","journal-title":"Clin Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2217\/14796678.2.3.335","article-title":"Cardioprotective role for angiotensin-(1-7) and angiotensin converting enzyme 2 in the heart","volume":"2","author":"Tallant","year":"2006","journal-title":"Futur Cardiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3389\/fphys.2015.00392","article-title":"Effect of angiotensin(1-7) on heart function in an experimental rat model of obesity","volume":"6","author":"Blanke","year":"2015","journal-title":"Front Physiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s11906-014-0420-5","article-title":"ACE2: angiotensin II\/angiotensin-(1\u20137) balance in cardiac and renal injury","volume":"16","author":"Varagic","year":"2014","journal-title":"Curr Hypertens Rep."},{"key":"B46","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.phrs.2016.02.026","article-title":"Long-term administration of angiotensin (1-7) prevents heart and lung dysfunction in a mouse model of type 2 diabetes (db\/db) by reducing oxidative stress, inflammation and pathological remodeling","volume":"107","author":"Papinska","year":"2016","journal-title":"Pharmacol Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.3389\/fimmu.2019.02885","article-title":"Improving the innate immune response in diabetes by modifying the renin angiotensin system","volume":"10","author":"Soto","year":"2019","journal-title":"Front Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"11903","DOI":"10.1038\/s41598-017-12074-3","article-title":"Ang-(1-7) is an endogenous \u03b2-arrestin-biased agonist of the AT1 receptor with protective action in cardiac hypertrophy","volume":"7","author":"Teixeira","year":"2017","journal-title":"Sci Rep."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1161\/HYPERTENSIONAHA.116.08118","article-title":"Cardioprotective angiotensin-(1\u20137) peptide acts as a natural-biased ligand at the angiotensin II type 1 receptor","volume":"68","author":"Galandrin","year":"2016","journal-title":"Hypertension."},{"key":"B50","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1161\/01.HYP.0000160325.59323.b8","article-title":"Angiotensin-(1\u20137) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats","volume":"45","author":"Walters","year":"2005","journal-title":"Hypertension."},{"key":"B51","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1471-4159.2009.05912.x","article-title":"Angiotensin-(1-7) through AT receptors mediates tyrosine hydroxylase degradation via the ubiquitin-proteasome pathway","volume":"109","author":"Verrilli","year":"2009","journal-title":"J Neurochem."},{"key":"B52","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.regpep.2004.03.005","article-title":"Angiotensin II and angiotensin-(1\u20137) inhibit the inner cortex Na+-ATPase activity through AT2 receptor","volume":"120","author":"Souza","year":"2004","journal-title":"Regul Pept."},{"key":"B53","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1161\/01.HYP.0000175813.04375.8a","article-title":"Evidence for a functional interaction of the angiotensin-(1\u20137) receptor mas with AT 1 and AT 2 receptors in the mouse heart","volume":"46","author":"de Castro","year":"2005","journal-title":"Hypertension."},{"key":"B54","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1042\/BJ20040634","article-title":"Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism","volume":"383","author":"Rice","year":"2004","journal-title":"Biochem J."},{"key":"B55","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1161\/01.HYP.31.4.912","article-title":"N-domain\u2013specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1\u20137) and keto-ACE","volume":"31","author":"Deddish","year":"1998","journal-title":"Hypertension."},{"key":"B56","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1161\/01.HYP.38.1.95","article-title":"Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade","volume":"38","author":"Tom","year":"2001","journal-title":"Hypertension."},{"key":"B57","doi-asserted-by":"publisher","first-page":"8258","DOI":"10.1073\/pnas.1432869100","article-title":"Angiotensin-(1\u20137) is an endogenous ligand for the G protein-coupled receptor Mas","volume":"100","author":"Santos","year":"2003","journal-title":"Proc National Acad Sci USA."},{"key":"B58","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1161\/HYPERTENSIONAHA.116.07572","article-title":"G-protein-coupled receptor MrgD is a receptor for angiotensin-(1-7) involving adenylyl cyclase, cAMP, and phosphokinase A","volume":"68","author":"Tetzner","year":"2016","journal-title":"Hypertens Dallas Tex 1979."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40695-015-0012-9","article-title":"Rheumatic autoimmune diseases in women and midlife health","volume":"1","author":"Marder","year":"2015","journal-title":"Women's Midlife Health."},{"key":"B60","first-page":"1439","article-title":"Taking ACE inhibitors during early pregnancy: is it safe?","volume":"53","author":"Ray","year":"2007","journal-title":"Can Fam Physician."},{"key":"B61","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1357-2725(02)00273-X","article-title":"Bradykinin, angiotensin-(1\u20137), and ACE inhibitors: how do they interact?","volume":"35","author":"Tom","year":"2003","journal-title":"Int J Biochem Cell Biol."},{"key":"B62","first-page":"125","article-title":"Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy","volume":"3","author":"Schindler","year":"2007","journal-title":"Vasc Heal Risk Manag."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1177\/0961203318768889","article-title":"Mesenchymal stem cell transplantation in systemic lupus erythematous, a mesenchymal stem cell disorder:","volume":"27","author":"Fathollahi","year":"2018","journal-title":"Lupus."},{"key":"B64","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3389\/fcell.2019.00285","article-title":"Mesenchymal stem cells: allogeneic MSC may be immunosuppressive but autologous MSC are dysfunctional in lupus patients","volume":"7","author":"Cheng","year":"2019","journal-title":"Front Cell Dev Biol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-018-0898-x","article-title":"Genetic contribution to mesenchymal stem cell dysfunction in systemic lupus erythematosus","volume":"9","author":"Zhu","year":"2018","journal-title":"Stem Cell Res Ther."},{"key":"B66","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13287-019-1538-9","article-title":"Efficacy of mesenchymal stem cells in animal models of lupus nephritis: a meta-analysis","volume":"11","author":"Zhou","year":"2020","journal-title":"Stem Cell Res Ther."},{"key":"B67","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00280-005-0078-4","article-title":"Phase I\/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer","volume":"57","author":"Rodgers","year":"2006","journal-title":"Cancer Chemother Pharmacol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s00280-013-2089-x","article-title":"Pharmacodynamic stimulation of thrombogenesis by angiotensin (1-7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy","volume":"71","author":"Pham","year":"2013","journal-title":"Cancer Chemother Pharmacol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1089\/wound.2014.0609","article-title":"NorLeu3-angiotensin (1-7) [DSC127] as a therapy for the healing of diabetic foot ulcers","volume":"4","author":"Rodgers","year":"2015","journal-title":"Adv Wound Care."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01572\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T09:02:22Z","timestamp":1595581342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01572\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,23]]},"references-count":69,"alternative-id":["10.3389\/fimmu.2020.01572"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.01572","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,23]]},"article-number":"1572"}}